Pavuluri Pratyusha, Menon M Girija, Tummalacharla Sarat Chandan, Sameer Raheem Shaik, Karpay Soujanya, Chepuri Phanindra
Biochemistry, RVM Institute of Medical Sciences and Research Center, Hyderabad, IND.
Cureus. 2024 Dec 4;16(12):e75120. doi: 10.7759/cureus.75120. eCollection 2024 Dec.
Introduction The COVID-19 pandemic originated in Wuhan, China, and swiftly spread across all continents. The respiratory system is the most affected in people who acquire sickness as a result of SARS-CoV-2. However, the virus can also affect other systems. The COVID-19 pandemic has become one of the most fatal infectious diseases in the recent past. Patients present with symptoms of fever, cough, tiredness, loss of taste or smell, sore throat, headache, and diarrhea. Objective This study intends to evaluate how COVID-19 has shown its effects on the well-being of the liver by collecting and correlating the data of the liver enzymes and inflammatory markers among hospitalized COVID-19 patients with age- and sex-matched healthy controls. Materials and methods A retrospective case-control study that included 200 patients diagnosed and hospitalized with COVID-19 was compared with an equal number of age- and sex-matched healthy control groups without COVID-19 at RVM Institute of Medical Sciences and Research Centre (RVMIMS & RC), a tertiary care teaching hospital in Siddipet, Telangana, India. Liver function tests (LFTs) and inflammatory markers were evaluated in both groups. Results Out of 200 patients, 179 (89.5%) had elevated alanine transaminase (ALT), 191 (95.5%) had elevated aspartate aminotransferase (AST), 33 (16.5%) had elevated alkaline phosphatase (ALP), and 183 (91.5%) showed elevated D-dimer levels. All the patients had elevated interleukin-6 (IL-6) and C-reactive protein (CRP) levels. Conclusion COVID-19 patients have exhibited elevations in liver enzyme panels and inflammatory markers. Further research and follow-up studies may aid in understanding the role of the well-being of the liver in patients affected by COVID-19. Considering the emergence of newer COVID-19 strains, we recommend LFT to patients who test positive for the virus to monitor prognosis and guide treatment protocols through this study.
引言
新冠疫情起源于中国武汉,并迅速蔓延至各大洲。感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人群中,呼吸系统受影响最为严重。然而,该病毒也会影响其他系统。新冠疫情已成为近期最致命的传染病之一。患者表现出发热、咳嗽、疲劳、味觉或嗅觉丧失、喉咙痛、头痛和腹泻等症状。
目的
本研究旨在通过收集并对比新冠住院患者与年龄和性别匹配的健康对照者的肝酶和炎症标志物数据,评估新冠对肝脏健康的影响。
材料与方法
在印度特伦甘纳邦西迪佩特的一家三级护理教学医院——RVM医学科学与研究中心(RVMIMS & RC),进行了一项回顾性病例对照研究,将200例确诊并住院的新冠患者与同样数量的年龄和性别匹配、未感染新冠的健康对照组进行比较。对两组进行肝功能检查(LFTs)和炎症标志物评估。
结果
200例患者中,179例(89.5%)丙氨酸转氨酶(ALT)升高,191例(95.5%)天冬氨酸转氨酶(AST)升高,33例(16.5%)碱性磷酸酶(ALP)升高,183例(91.5%)D-二聚体水平升高。所有患者白细胞介素-6(IL-6)和C反应蛋白(CRP)水平均升高。
结论
新冠患者的肝酶指标和炎症标志物出现升高。进一步的研究和随访研究可能有助于了解肝脏健康在新冠感染患者中的作用。鉴于新的新冠毒株不断出现,通过本研究,我们建议对病毒检测呈阳性的患者进行肝功能检查,以监测预后并指导治疗方案。